Insights from 2023 EHA® Annual Meeting

 

Insights from 2023 EHA® Annual Meeting
Avatar

EHA® 2023 Insights: "Disease-Modifying Activity of Navtemadlin Correlated With Survival Outcomes in JAKi R/R Myelofibrosis Patients"

By Insights from 2023 EHA® Annual Meeting FEATURING Pankit Vachhani
By Insights from 2023 EHA® Annual Meeting FEATURING Pankit Vachhani
123 views
June 20, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

07:44
Incyte

Optimizing the Management of Patients with Polycythemia Vera (PV)

Feat. P. Bose, R. Rampal
MDS and MPN
12:44

EHA® 2023 Insights: "Disease-Modifying Activity of Navtemadlin Corre…

Insights from 2023 EHA® Annual Meeting

P. Vachhani

123 views